Drug-resistant TB: latest news

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • All-access for blockbuster TB drug in South Africa

    The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

    19 June 2018 | Health-e
  • Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?

    As tuberculosis (TB) is the world's most lethal infectious disease, there is an urgent need to improve the treatment of this bacterial infection. One approach under consideration is the institution of a universal or “pan-TB” regimen comprising new agents capable of treating multidrug-resistant (MDR) and even extensively drug-resistant (XDR) TB.

    29 May 2018 | Infectious Disease Advisor
  • Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it

    Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last resort, fewer than a fifth of patients needing them have received them, according to a report in the International Journal of Tuberculosis and Lung Disease.

    06 April 2018 | Science Speaks
  • WHO issues recommendations on management of isoniazid-resistant tuberculosis

    Within the context of an ongoing extensive review of evidence on treatment of drug-resistant (TB) taking place in 2018, the World Health Organization (WHO) has issued a Supplement to its current drug-resistant TB treatment guidelines, providing recommendations for the management of isoniazid-resistant TB. These will be incorporated into the Consolidated Guidelines for Treatment and Care of Drug-resistant TB envisaged by WHO later in 2018.

    22 March 2018 | World Health Organization
  • J&J, Macleods in talks for licence deal of tuberculosis drug

    Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson(J&J) are in talks for a voluntary licence deal for the tuberculosis drug Bedaquiline, EThas learnt.

    13 March 2018 | Economic Times
  • How both sides in Ukraine's war are losing the HIV battle

    Displacement, aid delivery issues, and different strategies are all feeding a raging epidemic.

    16 February 2018 | IRINnews.org
  • Promising MSF Research Highlights Immense Benefits, Need for Expanded Use of DR-TB Drug Combination

    New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.

    14 February 2018 | MSF press release
  • TB treatment outcomes good for multidrug-resistant TB/HIV co-infected patients who start ART

    Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy.

    01 February 2018 | Medical Brief
  • A global study reveals new TB mutations that could transform tests for drug resistance

    Resistance to the antibiotics used to treat TB is caused by mutations in the bacterial genome and new rapid molecular (DNA) tests are being developed, but detecting resistance relies on knowing which mutations to look for…. and there are potentially hundreds of mutations.

    24 January 2018 | London School of Hygiene and Tropical Medicine
  • People still being denied improved treatment for multidrug-resistant TB

    People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

    16 October 2017 | Médecins Sans Frontières (MSF) International
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.